Augtyro (repotrectinib) — United Healthcare
non-small cell lung cancer (ROS1-positive)
Initial criteria
- Diagnosis of non-small cell lung cancer (NSCLC)
- Disease is advanced OR metastatic
- Disease is ROS1-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Augtyro therapy
Approval duration
12 months